类风湿关节炎诊断前的血清蛋白质组特征:演化中的生物学通路与疾病发展的特定时期
该纵向病例对照研究在美国国防部血清库中纳入213例符合1987年美国风湿病学会分类标准的类风湿关节炎患者与215例无类风湿关节炎的匹配对照,检测诊断前后血清中类风湿关节炎相关自身抗体及197种蛋白质。结果显示抗CCP3、RFIgA和RFIgM在诊断前≤5年差异最大,104种蛋白质差异表达并关联32条通路,其中21条在诊断前≤5年富集;一组特征可分类诊断前<3年的样本,训练集ROC曲线下面积0.78(95%CI 0.67-0.89),验证集0.80(95%CI 0.68-0.92)。
要点
- 抗CCP3、RFIgA和RFIgM在类风湿关节炎诊断前≤5年与对照差异最大。
- 104种蛋白质在诊断前差异表达,其中60种在诊断前≤5年差异表达,42种在诊断前5年内及之前差异表达,2种在诊断前>5年差异表达。
- 抗CCP抗体阳性样本中一组特征可分类诊断前<3年的样本,训练集ROC曲线下面积0.78(95%CI 0.67-0.89),验证集0.80(95%CI 0.68-0.92)。
核心结论
- 自身抗体和蛋白质特征在类风湿关节炎诊断前以不同阶段演化,蛋白质生物标志物可能识别与特定阶段相关的生物学通路,这些可进一步探索以潜在改善疾病发作预测并识别可用于预防干预的阶段特异性生物学通路。
研究设计与样本
- 纵向病例对照研究,在美国国防部血清库中纳入213例符合1987年美国风湿病学会分类标准的类风湿关节炎患者和215例无类风湿关节炎的匹配对照,检测诊断前后血清中类风湿关节炎相关自身抗体(抗环瓜氨酸肽3抗体和类风湿因子IgM、IgA同种型)及197种蛋白质(Olink商业平台),采用线性混合效应模型分析。
主要发现
- 抗CCP3、RFIgA和RFIgM水平在类风湿关节炎诊断前≤5年患者与对照间差异最大。
- 纵向分析识别104种蛋白质在患者与对照间差异表达:60种在诊断前≤5年差异表达,42种在诊断前5年内及之前差异表达,2种在诊断前>5年差异表达。
- 京都基因与基因组百科全书分析显示这些蛋白质关联32条通路,其中21条在诊断前≤5年富集。
- 在诊断前抗CCP抗体阳性样本与对照中,一组特征可分类样本是否来自类风湿关节炎诊断前<3年,训练集ROC曲线下面积0.78(95%CI 0.67-0.89),验证集0.80(95%CI 0.68-0.92)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This longitudinal case-control study evaluated serum proteomics before a clinical diagnosis of rheumatoid arthritis (RA) (ie, pre-RA) to evaluate biologic pathways of disease development and inform prediction of timing of onset of future disease. METHODS: Patients (n = 213) meeting the 1987 American College of Rheumatology classification criteria for RA and matched controls without RA (n = 215) were identified in the Department of Defense Serum Repository. Serum samples from patients before and after RA diagnosis and controls were tested for RA-related autoantibodies (anti-cyclic citrullinated peptide-3 [anti-CCP3] and rheumatoid factor [RF] isotypes IgM and IgA) and 197 proteins using a commercial platform (Olink). We applied linear mixed effect models to identify biomarkers distinguishing patients from controls before RA diagnosis and analyzed longitudinal patterns of enriched pathways; in addition, models were developed to classify the time of a sample in relationship to the time of RA diagnosis. RESULTS: Levels of anti-CCP3, RFIgA, and RFIgM demonstrated the greatest differences between patients and controls ≤5 years before RA diagnosis. Longitudinal analyses identified 104 proteins that were differentially expressed between patients and controls; 60 proteins were differentially expressed ≤5 years before diagnosis, 42 proteins were differentially expressed within and before five years of diagnosis, and 2 proteins were differentially expressed >5 years before diagnosis. Kyoto Encyclopedia of Genes and Genomes analyses identified that these proteins were associated with 32 pathways, including 21 pathways that were enriched ≤5 years before diagnosis. Within the anti-citrullinated protein antibody-positive samples from before RA diagnosis and controls, a set of features classified if that sample was from a period <3 years before RA diagnosis, with an area under the receiver operating characteristic (ROC) curve of 0.78 (95% confidence interval 0.67-0.89) in a training set and 0.80 (0.68-0.92) in a validation set. CONCLUSION: Autoantibodies and protein signatures evolve in distinct stages before a diagnosis of RA. Furthermore, protein biomarkers may identify biologic pathways relevant to specific stages. These can be further explored to potentially improve prediction of disease onset and identify stage-specific biologic pathways to target with preventive interventions.
引用
- Rachid Zaim S, Savage AK, Gillespie MA, et al. Serum Proteomic Signatures Before the Diagnosis of Rheumatoid Arthritis: Evolving Biologic Pathways and Specific Periods of Disease Development. Arthritis Rheumatol. 2025. PMID: 40189919. doi:10.1002/art.43175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。